Beta Bionics Announces Pricing of Upsized $204 Million Initial Public Offering
Rhea-AI Summary
Beta Bionics has announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at $17.00 per share, expecting to raise gross proceeds of $204.0 million. The company's shares will begin trading on the Nasdaq Global Market on January 30, 2025, under the ticker symbol BBNX.
The underwriters have a 30-day option to purchase up to an additional 1,800,000 shares. Additionally, Beta Bionics has agreed to sell 1,000,000 shares in a concurrent private placement at the same price, bringing the total potential gross proceeds to $221.0 million before expenses.
The offering is expected to close on January 31, 2025. BofA Securities, Piper Sandler, and Leerink Partners are acting as lead bookrunners, with Stifel as bookrunner and Lake Street Capital Markets as co-manager.
Positive
- Successful upsized IPO raising $204.0 million in gross proceeds
- Additional $17 million secured through concurrent private placement
- Strong underwriting support from major financial institutions
- Listing on Nasdaq Global Market enhances visibility and liquidity
Negative
- Potential dilution from additional 1.8 million shares if underwriters exercise their option
- Company will not receive proceeds from selling stockholders' shares
- Significant offering expenses and underwriting discounts will reduce net proceeds
Insights
The successful pricing of Beta Bionics' upsized IPO at
The concurrent
The combined
The 30-day overallotment option for an additional 1.8 million shares provides flexibility for price stabilization, though the split between company and selling stockholder shares (
Beta Bionics' successful IPO marks a pivotal moment in the evolution of automated insulin delivery systems. The company's iLet Bionic Pancreas system represents a significant advancement in closed-loop insulin delivery technology, potentially offering improved glycemic control compared to traditional insulin pumps.
The substantial
The strong investor response reflects growing confidence in next-generation diabetes management technologies, particularly those leveraging artificial intelligence and automation. Beta Bionics' dual-hormone approach, capable of delivering both insulin and glucagon, positions it uniquely in the market. The capital raised should support both ongoing R&D efforts and the critical phase of market penetration, where education and adoption by healthcare providers will be key success factors.
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at a price to the public of
The shares are expected to begin trading on the Nasdaq Global Market on January 30, 2025 under the ticker symbol “BBNX.” The offering is expected to close on January 31, 2025, subject to the satisfaction of customary closing conditions.
BofA Securities, Piper Sandler and Leerink Partners are acting as lead bookrunners for the proposed offering. Stifel is acting as a bookrunner and Lake Street Capital Markets is acting as co-manager for the offering.
Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on January 29, 2025. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering was made only by means of a prospectus forming part of the registration statements relating to these securities. When available, copies of the final prospectus relating to the initial public offering may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, or by email at prospectus@psc.com; or Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com.
In addition, Beta Bionics has agreed to sell 1,000,000 shares of its common stock in a concurrent private placement to one of its existing investors at the initial public offering price of
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD.
Investor Relations Contact:
Blake Beber, Head of Investor Relations, ir@betabionics.com
Media and Public Relations Contact:
Karen Hynes, Vice President of Marketing, media@betabionics.com
FAQ
What is the IPO price for Beta Bionics (BBNX) shares?
How much money did Beta Bionics raise in its IPO?
When will BBNX start trading on Nasdaq?
How many shares did Beta Bionics offer in its IPO?
Who are the lead underwriters for the BBNX IPO?
